00:35 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

AC-1204: Ph III NOURISH AD data

Top-line data from the double-blind, U.S. Phase III NOURISH AD trial in about 418 non-carriers of apolipoprotein E (APOE) epsilon 4 (APOE4) with mild to moderate AD showed that once-daily 40 g oral AC-1204 missed...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
20:14 , Feb 28, 2017 |  BC Extra  |  Clinical News

Accera attributes Phase III AD failure to bioavailability issue

Accera Inc. (Boulder, Colo.) said AC-1204 missed the primary endpoint in the Phase III NOURISH AD trial to treat mild to moderate Alzheimer's disease. Compared with placebo, the candidate failed to significantly improve AD Assessment...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

AC-1204: Completed Phase III enrollment

Accera completed enrollment of >400 patients with mild to moderate AD in the double-blind, placebo-controlled, U.S. Phase III NOURISH AD trial evaluating once-daily oral AC-1204 for 26 weeks. NOURISH AD includes a 26-week open-label extension....